drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous T cells genetically engineered to express a CAR with an FMC63 anti-CD19 scFv, CD28 hinge/transmembrane, and intracellular CD3ε, CD28, and CD3ζ signaling domains; given as a single IV infusion to eliminate CD19+ B cells and reset humoral immunity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered with an FMC63 anti‑CD19 scFv linked to CD28 hinge/transmembrane and intracellular CD3ε, CD28, and CD3ζ signaling domains. Upon binding CD19 on B cells, the CAR delivers activation and costimulatory signals that drive T‑cell cytotoxicity (perforin/granzyme) and cytokine release, depleting CD19+ B‑cell populations to ablate autoreactive clones and reset humoral immunity.
drug_name
Autologous anti-CD19-CD3E CAR-T cells
nct_id_drug_ref
NCT06373081